Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics

Bio-Rad Laboratories, Inc. (BIO)

Today's Latest Price: $589.19 USD

11.62 (-1.93%)

Updated Jan 21 4:00pm

Add BIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BIO Stock Summary

  • BIO's went public 35.08 years ago, making it older than 92.82% of listed US stocks we're tracking.
  • BIO's current price/earnings ratio is 5.09, which is higher than just 3.91% of US stocks with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, Bio-Rad Laboratories Inc is reporting a growth rate of 736.88%; that's higher than 98.11% of US stocks.
  • Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are PKI, CERN, GNRC, ATHM, and SNN.
  • Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to

BIO Stock Price Chart Interactive Chart >

Price chart for BIO

BIO Price/Volume Stats

Current price $589.19 52-week high $648.39
Prev. close $600.81 52-week low $309.38
Day low $586.17 Volume 258,499
Day high $601.41 Avg. volume 255,687
50-day MA $578.38 Dividend yield N/A
200-day MA $515.34 Market Cap 17.58B

Bio-Rad Laboratories, Inc. (BIO) Company Bio

Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.

BIO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$589.19$258.37 -57%

Below please find a table outlining a discounted cash flow forecast for BIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Bio-Rad Laboratories Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 196.01 -- which is good for besting 97.7% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 14% of the free cash flow producing stocks we're observing.
  • BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 45.83% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Bio-Rad Laboratories Inc? See MD, BAX, GILD, HAPP, and JNJ.

BIO Latest News Stream

Event/Time News Detail
Loading, please wait...

BIO Latest Social Stream

Loading social stream, please wait...

View Full BIO Social Stream

Latest BIO News From Around the Web

Below are the latest news stories about Bio-Rad Laboratories Inc that investors may wish to consider to help them evaluate BIO as an investment opportunity.

Top Healthcare Stocks for February 2021

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Yahoo | January 19, 2021

Cancer Biomarkers Market | BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.

Coherent Market Insights released a new market study on 2020-2027 Cancer Biomarkers Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence.

OpenPR | January 18, 2021

Liquid Biopsy Market Size, Outlook, Opportunities and Forecasts Report 2020-2027 | Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Myriad Genetics, Janssen Diagnostics, LLC

Global Liquid Biopsy Market research report provides an in-depth analysis of the industry and economy-wide database for the business management that could potentially offer development and profitability for players in this market. The Liquid Biopsy Market report discusses all major

OpenPR | January 15, 2021

Global Bacterial and Plasmid Vectors Market Report 2020-2023 & 2030: COVID-19 Impacts, Growth and Change -

DUBLIN--(BUSINESS WIRE)--The "Bacterial and Plasmid Vectors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to's offering. Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs. The global bacterial and plasmid vectors market is expected to decli

Business Wire | January 12, 2021

A Trio of High Earnings Return Stocks

They are thrashing the 20-year high-quality market corporate bonds

Yahoo | January 10, 2021

Read More 'BIO' Stories Here

BIO Price Returns

1-mo 0.98%
3-mo 1.29%
6-mo 14.24%
1-year 55.66%
3-year 131.37%
5-year 363.67%
YTD 1.07%
2020 57.54%
2019 59.34%
2018 -2.70%
2017 30.94%
2016 31.46%

Continue Researching BIO

Want to see what other sources are saying about Bio-Rad Laboratories Inc's financials and stock price? Try the links below:

Bio-Rad Laboratories Inc (BIO) Stock Price | Nasdaq
Bio-Rad Laboratories Inc (BIO) Stock Quote, History and News - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0152 seconds.